rituximab,cyclophosphamide
biogen,roche
[]
 abs 0003 maher, et al.
recital rct: rtx vs cyc for ctd-ild 1* outcome change fvc at 24wks - greatest benefit iim, mctd
ssc-ild: but not improved #acr22
@bu_bmc_rheum | @rheum_covid @spartan_updates @official_asas | @UWRheum @UWEpidemiology 2020 | @OHSUIMres 2017 | @UTMBhealth 2014 | @UTAustin 2010